Reports Q2 revenue $1.3M vs. $0.1M last year. As of June 30, Inhibrx (INBX) had cash and cash equivalents of $186.6M vs. $216.5M as of March 31. The decrease in EPS was primarily related to the $2.0B gain recorded in connection with the completion of the 101 Transaction in Q2 of 2024, offset in both periods by operational losses.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBX: